MSD states “Keytruda is an innovative antibody that will create its own pipeline itself”

The pharmaceutical industry has paid attention on the domestically first anti-PD-1 immunotherapy ‘Keytruda’.

On the 14^th, MSD Korea announced that it held a press conference to introduce the role and clinical benefit of an immunotherapy as a new antibody paradigm and the research result of clinical trials of Keytruda (pembrolizumab), celebrating the approval of Keytruda from the Ministry of Fo...